DxCover
Developing a spectroscopic liquid biopsy for rapid detection of cancer.
- B2B
- manufacturing
- commission
- health
- medical devices
- health platform
- biotechnology
- recognition technology
- deep tech
- artificial intelligence
- dt and ls
- biotechnology
- horizon europe
- sustainable development goals
- biotech and pharma
- spinout
- core ai
- ai applications
- oncology
- neurology
- health it
- nif defense security and resilience
- ai drug discovery
- techbio
- physician support tools
- medical diagnostics
- techbio drug discovery
- clinical decision support
- nif health crisis preparedness
- nif biotech
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
* | £5.0m Valuation: £37.5m | Early VC | |
| Total Funding | 000k | ||
Related Content
DxCover is a clinical-stage liquid biopsy company that has developed the PANAROMIC™ platform for early detection of multiple cancers. The company's technology, known as Multi-Omic Spectral Analysis (MOSA-Dx), analyzes the biochemical profile of a patient's blood serum using infrared spectroscopy and artificial intelligence to identify the presence or absence of disease.
DxCover's platform is designed to provide rapid, cost-effective, and non-invasive cancer diagnostics. The company is currently conducting clinical trials for the detection of brain, colorectal, and lung cancers. By detecting cancers at an earlier stage, DxCover aims to improve patient outcomes and reduce healthcare costs. The company's business model is focused on the development and commercialization of its diagnostic tests for use in clinical settings, such as hospitals and laboratories.
Keywords: liquid biopsy, cancer diagnostics, early detection, artificial intelligence, spectroscopy, multi-omic, PANAROMIC, MOSA-Dx, clinical trials, non-invasive